The Real Story Behind Lupin’s 10 Press Releases

Every pharma press release is a small, unremarkable-looking door. Behind each one is either a dead end or a room that connects to something larger. Lupin’s news flow between February and April 2026, ten announcements in eleven weeks, is worth reading as a sequence rather than as individual items, because the doors all lead to the same place.

The story is straightforward, even if the drug names aren’t: Lupin spent most of the last decade trying to escape the part of the pharmaceutical business where the only way to compete is to be cheaper than the other guy. Standard generics copies of off-patent drugs, sold on price, are a reasonable business until they aren’t. When too many manufacturers chase the same molecules, margins compress, and the business starts to look less like pharmaceuticals and more like commodities. Lupin saw this coming, and the press releases from the past three months show how far along the escape has gotten.

The US: Harder Molecules

Five of the ten announcements were about the US market. None of them was for simple tablets. A cancer drug called Dasatinib targets leukaemia patients and references a branded market of nearly USD 1 billion. Brivaracetam is a liquid formulation for epilepsy, approved for infants as young as one month old. Topiramate extended-release controls exactly how fast a drug dissolves over time. A class of diabetes drugs called Dapagliflozin and its combination with metformin are SGLT2 inhibitors that have grown well beyond their original indication into heart failure and kidney disease.

The common thread is formulation complexity. Oral solutions for babies, extended-release capsules, fixed-dose combinations of two drugs with different pharmacological profiles, these are technically harder to make than a standard tablet. And because they’re harder to make, fewer manufacturers file for them, which means fewer competitors at launch, which means the price doesn’t collapse on day one. That’s not a small thing. It’s the reason Lupin’s gross margin in Q3FY26 came in at 73.5%, compared to 69.4% a year earlier. The mix is shifting, and margins are following.

The drugs are getting harder to make. That’s the point. Harder to make means fewer competitors. Fewer competitors mean better pricing. Better pricing means the margins you can see in the Q3 numbers.

Two more US approvals for Sugammadex (used to reverse anaesthesia in surgery) and Pitolisant (for narcolepsy) are sitting as tentative approvals, meaning the FDA has cleared them but a patent period on the branded drug hasn’t expired yet. They’re launches in waiting. They show that the pipeline is deeper than whatever is selling today.

Europe: A Different Kind of Ambition

Two European announcements, read separately, look like unrelated events. The European Commission approved Lupin’s biosimilar ranibizumab, an injectable eye drug for conditions like wet macular degeneration that can cause blindness. And Lupin acquired VISUfarma, an ophthalmology-focused speciality pharma company with €53 million in revenues and commercial teams across Italy, the UK, Spain, Germany, and France.

Read together, these are one decision, not two. A biosimilar is only as valuable as the commercial infrastructure behind it. Retinal drugs are prescribed by specialists, not GPs, not pharmacists, which means you need a dedicated sales force with ophthalmology relationships to sell them. VISUfarma has exactly that, built over years in exactly the markets where the biosimilar is now approved. Lupin manufactured the drug; the acquisition bought the channel to sell it through. That’s a complete business, not two separate bets.

It also signals something about how Lupin is approaching Europe. Most Indian generics companies treat European markets as a price-compression exercise to get the cheapest copy on the shelf. Lupin is building in Europe for a different kind of competition, one where you need both scientific credibility and physician relationships to win. Biosimilars are the entry ticket to that game. They require a biological manufacturing capability that regulators scrutinise far more intensively than for conventional generics. Getting EC approval is evidence that you’ve passed that scrutiny.

Partnerships: The Smaller Signals

Two partnership announcements round out the picture. In Canada, Lupin agreed to commercialise DeslaFlex, a novel antidepressant formulation for Major Depressive Disorder developed by a Canadian startup called Spektus. This is a branded, differentiated product, not a generic. Lupin’s Canadian team is being asked to sell something with a genuine clinical story, not just a cheaper alternative to an existing drug.

The TB Alliance collaboration is different in character. Lupin is providing manufacturing capability and supply chain support for Telacebec, an investigational drug for tuberculosis, leprosy, and Buruli ulcer. The commercial returns here are uncertain and long-dated. What it does is establish Lupin as a company whose manufacturing standards are trusted for global health programmes, the kind of institutional credibility that matters when regulated markets evaluate you as a supplier or partner for more complex products.

The Takeaway

Here is the one thing all ten press releases are saying: Lupin is no longer principally competing on price. The US launches target formulations with fewer competitors. The European moves combine biologic manufacturing with speciality commercial infrastructure. The Canadian deal is about a differentiated branded product. Even the TB collaboration is about demonstrating manufacturing quality, not cost.

The Q3FY26 numbers, 840 basis points of EBITDA margin expansion in a single year, record US sales, and a net cash balance sheet are what happen when this shift shows up in the financials. The announcements are the strategy. The earnings are the confirmation that it’s working.

_{Disclaimer: Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.}

_{The content in these posts/articles is for informational and educational purposes only and should not be construed as professional financial advice and nor to be construed as an offer to buy /sell or the solicitation of an offer to buy/sell any security or financial products.Users must make their own investment decisions based on their specific investment objective and financial position and using such independent advisors as they believe necessary.}

_{Windmill Capital Team: Windmill Capital Private Limited is a SEBI registered research analyst (Regn. No. INH200007645) based in Bengaluru at No 51 Le Parc Richmonde, Richmond Road, Shanthala Nagar, Bangalore, Karnataka – 560025 creating Thematic & Quantamental curated stock/ETF portfolios. Data analysis is the heart and soul behind our portfolio construction & with 50+ offerings, we have something for everyone. CIN of the company is U74999KA2020PTC132398. For more information and disclosures, visit our disclosures page here.}